September 9, 2026

Company name: Pharma Foods International Co., Ltd.
Representative: Mujo Kim, President
(Securities code: 2929 Prime Market)
Inquiries: Yoshiaki Aoki, Section Manager of Corporate Support Promotion, Investor Relations
(Telephone: +81-75-394-8600)

Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2026

Pharma Foods International Co., Ltd. (the "Company") hereby announces that, reflecting a comprehensive analysis of its current performance dynamics, the Company has revised the consolidated full-year financial results forecast for the fiscal year ended July 31, 2026 (August 1, 2025 to July 31, 2026), which was originally announced on March 13, 2026, as set forth below.

1. Revision of Consolidated Results Forecast for the Fiscal Year Ending July 2026

	Net Sales	Operating Profit	Ordinary Profit	Net Income Attributable to Owners of the Parent	Earnings per Share
	JPY (M)	JPY (M)	JPY (M)	JPY (M)	JPY
Previous Forecasts (A)	67,000	2,000	2,000	1,500	51.65
Revised Forecasts (B)	63,200	2,600	2,400	1,950	67.14
Change (B-A)	▲3,800	600	400	450	–
Change (%)	▲5.7%	30.0%	20.0%	30.0%	–
(Reference) Actual Consolidated Results for the Previous Fiscal Year ended July 31, 2024	65,260	2,367	2,553	368	12.83

2. Reasons for the Revision

The Company has pursued its medium-term management plan, "New Value Creation: 1K Project," and has worked to create new value through R&D based on its proprietary biotechnology and to develop high-value-added products in the healthcare sector.

In the B2B business, the Company's core functional ingredient "PharmaGABA" has been increasingly adopted by overseas manufacturers, particularly in North America and Thailand, resulting in expanded sales in these markets.

In the B2C business, sales of the Company's flagship "Newmo Series" remained strong, while sales of new products such as "LACTORON Tablets" and "TENRAI KIBO-KO Tablets" also increased. These new products have been steadily growing as new earnings pillars following the "Newmo Series."

In the textile business, the Company's proprietary eggshell membrane fiber "ovoveil" was selected for the Ministry of Economy, Trade and Industry's "Bio Manufacturing Revolution Promotion Project," and the Company has advanced R&D efforts to further enhance the value of the material. In addition, "ovoveil" received significant attention at the 2025 Osaka-Kansai Expo, resulting in numerous inquiries from major apparel brands in Japan and overseas.

In the drug discovery business, the Company entered into an exclusive license agreement with the National Cerebral and Cardiovascular Center (“NCVC”) for the development and commercialization of a treatment for CADASIL, a designated intractable disease by the Ministry of Health, Labor and Welfare. The Company is steadily preparing for joint clinical trials with NCVC with the aim of obtaining approval for a treatment for CADASIL, for which no established treatment is currently available.

Meanwhile, in response to changes in the business environment, the Company has been shifting its business management approach to place greater emphasis not only on sales growth, but also on profitability and capital efficiency. As a result of thoroughly prioritizing profitability in sales and investment activities and reviewing costs across each business segment, the Company expects to secure profits exceeding its initial plan.

Consequently, while net sales are expected to fall below the previous forecast, operating profit, ordinary profit, and net income attributable to owners of the parent are expected to exceed the previous forecast. Operating profit is also expected to exceed the actual results for the previous fiscal year.

Building on the R&D capabilities and business foundation cultivated through the medium-term management plan “New Value Creation: 1K Project” as the foundation for future growth, the Company will further shift toward a business structure that generates sustainable profits by placing greater emphasis not only on sales growth, but also on profitability and capital efficiency.